The mode of in vivo cell-killing by 15-deoxyspergualin (NKT-01) was assessed by measuring change of whole body radioactivity of mice inoculated with 125I-iododeoxyuridine-labeled P388 leukemia cells. Although NKT-01 showed strong life prolonging effect on P388 leukemia-bearing mice, significant excretion of 125I was not observed within 4 days after the start of treatment with NKT-01. Thereafter, the remaining 125I was reduced gradually and reached about half of control level on day 7. Colony forming ability in soft agar media of peritoneal tumor cells taken after completion of 5-day treatment with NKT-01was markedly reduced to less than 3%. These results suggested that life prolongation of NKT-01was produced both by a cytostatic effect, which lasts for an extraordinarily long period, and by a subsequent cytotoxic effect. Cell cycle distribution analysis using flow cytometry showed the cytostatic action of NKT-01caused GQjG1arrest of the tumor cells. Therefore, the drug-sensitive cycling population of the tumor cells was reduced, and combination with other antitumor agents was antagonistic, if they were administered simultaneously or consecutively with NKT-01.In contrast, if the other drugs such as cyclophosphamide, cisplatin and cytosine arabinoside, were administered prior to NKT-01,a synergistic combination effect was obtained. This synergism might be due to prolongation of the period of cell cycle perturbation caused by other drugs (such as G2 arrest by cisplatin) by the cytostatic effect of NKT-01. Although the precise mechanisms of the cytostatic action of NKT-01remain unclear, it might play an important role in the combination with other antitumor drugs.
15-Deoxyspergualin (NKT-01) is a synthetic derivative of spergualin (SGL), an antibiotic discovered from a culture filtrate of Bacillus laterosporus.ia) NKT-01and SGLexhibit antitumor activity against various leukemias both in vitro and in vivo.3~5) They also showed immunosuppressive activity and efficacy in organ transplantation in animals.6~8)
In spite of vigorous efforts, the details of the mechanismsof antitumor and immunosuppressiveaction remain unclear. Regarding the antitumor activity against highly sensitive tumors such as LI210 (IMC) leukemia, involvement of tumor-specific cytotoxic T-lymphocytes (CTL) was clearly demonstrated.9) The CTLare induced at lower doses of SGLand exhibit immunological antitumor effect to sensitive tumors in vivo in addition to direct cytocidal action. The direct action of SGLs was shown to be extremely dependent on the treatment period in growth inhibition experiments of cultured tumor cells as well as on the treatment schedule in vivo.3~5 '10) In the present study, we investigated the nature of the direct action of NKT-01in vivo. Weestimated the cell-killing in terms of (a) release of 125I from inoculated 125I-iododeoxyuridine-labeled P388 leukemia cells in mice after treatment with NKT-01, and (b) colony formation of P388 cells withdrawn from the peritoneal cavity of NKT-01-treated mice as the experimental endpoints. In adidition, the effect of NKT-01 NOV. 1991 on cell cycle traverse in vivo was examined by using flow cytometry. Wefurther describe the nature of action of NKT-01by assessing the combination effect of NKT-01with various types of antitumor agents in simultaneous and sequential treatment schedules in vivo.
Materials and Methods

Drugs
NKT-01 was prepared by Takara Shuzo Co., Ltd. (Ohtsu, Japan), dissolved in physiological saline, and stored in the dark at 4°C before use. Other antitumor drugs were purchased from commercial sources and dissolved in saline or distilled water just before use.
Mice and Tumors CD2FX(BALB/c x DBA/2) and C57BL/6 mice were purchased from Shizuoka Laboratory Animal Center (Hamamatsu, Japan). P388 leukemia is maintained by weekly transplantation in DBA/2 mice and inoculated into CD2Fl mice for in vivo experiments. M5076fibrosarcoma is maintained and used for experiment by sc implantation into C57BL/6 mice.
Labeling of P388 Leukemia Cells with 125Mododeoxyuridine P388 cells collected from peritoneal cavity were cultured in RPMI-1640 supplemented with 10% fetal calf serum, 5^m 2-mercaptoethanol and 60/ig/ml kanamycin in a spinner culture bottle at 37°C in 5% CO2. After 1 day preculture, exponentially growing cells (8.8 x 104/ml) were labeled by an addition of 125I-5-iodo-2'-deoxyuridine (125IUdR) (New England Nuclear Research Products (Boston, MA)) at the concentration of2.5 nCi/ml for 1 day. Labeled cells were washed 3 times and suspended in Hanks' balanced salt solution. Viability of the cells was determined by the trypan blue dye exclusion method, and incorporation of 125IUdR into cells was measured with a Beckman model Gamma8000 gamma spectrometer.
Determination of Cell Death CD2FX mice were given 0.1%Nal-supplemented water to minimize accumulation of 125I in thyroid gland, and inoculated ip with 2 x 107 labeled P388 cells in 0.5ml. Administration of NKT-01, cisplatin (CDDP) or 5-fluorouracil (5-FU) was started 4 hours after the inoculation. Remaining 125I in mice was monitored daily by counting the whole body radioactivity by inserting live mice into a plastic holder for the gammaspectrometer.n) Measured radioactive counts of 125I were compensated for radioactive decay of the isotope, and compared to the initial count.
Colony Formation of P388 Leukemia Cells Mice were inoculated with 2 x 107/0.5ml of P388 cells and treated with NKT-01once a day for 5 days. The day after the final injection, P388 cells were collected from the peritoneal cavity and washed twice by centrifugation. The cells were suspended in culture mediumand then mixed with noble agar solution at a final concentration of 0.1%. After incubation for 18 days at 37°C in 5% CO2, numbers of colonies formed were counted. Surviving fraction was calculated by comparing the colony forming efficiency of cells from NKT-01-treated mice with that from control mice. Combination effects were estimated by a combination index (CI), which was calculated as a ratio of ILS (%) in combination to the sum of ILS (%)'s of two single-drug-treated groups. When CI equals to 1, it means the combination effect is just additive. CI value more, or less than 1 means synergistic, or antagonistic effect, respectively. 1 3)
In the combination experiments of sc inoculated M5076 fibrosarcoma (106 cells), CI was based on the tumor growth delay, which was determined from time to reach 500mm3in tumor volume. Tumor volume was calculated as follows; tumor volume=Lx W2/2, where L and Ware length and width of tumor mass, respectively.
Results
Mode of Cell-killing of To examine the features by cell-killing of NKT-01in vivo, we monitored direct cell death by NKT-01 by the 125I release method, and compared with those by CDDPand 5-FU. Excretion of 125I from mice inoculated with 125IUdR-labeled P388 cells was determined after starting the drug administration ( Fig. 1 ). Gradual decrease in remaining radioactivity in control mice was observed, which seemed to be due to excision repair of 125IUdR-incorporated DNA. Nodifference in excretion of 125I from mice was observed between the control mice and NKT-01-treated mice within 4 days after tumor inoculation. Excretion of 125IUdR due to cell death by NKT-01 was observed from day 5, and reached about half of control level on day 7. However, the life prolonging effect of NKT-01 could not be explained only by this small degree of cell-killing detected by 125I excretion. These results suggest that NKT-01acts on tumor cells in cytostatic manner in the early period and then repeatedly treated tumor cells with NKT-01 were gradually killed and excreted. In contrast to NKT-01, rapid decrease in remaining 125I was observed immediately after CDDPtreatment, and remaining radioactivity on day 7 decreased to about 10% of control level. Although 5-FU exhibited stronger life prolonging effect (shown in parentheses in Fig. 1 ) than single injection of CDDPand comparable activity to 5-day treatment of CDDP,the excretion of 125IUdR was delayed and the remaining level on day 7 was larger than that of mice treated with CDDPby either treatment schedule.
Therefore, these results indicate that cell cycle non-specific cytotoxic agents such as CDDPkill tumor cells immediately, while the cell cycle specific antimetabolites such as 5-FU exhibit cytotoxic effects after some delay. From this viewpoint, to demonstrate its cell-killing action, NKT-01requires extraordinarily longer period as compared with other cell cycle specific drugs such as 5-FU.
To determine the actual cell viability after 5-day treatment with NKT-01, clony forming ability of P388 cells treated with NKT-01in vivo was determined in soft agar. As shown in Table 1 , 5-day treatment with NKT-01strongly reduced cellular viability to form colonies. Therefore, it was confirmed that cells were committed to death after the 5-day treatment (day 6), even though cells were not killed in the early phase (up to day 4 as shown in Fig. 1 ).
Combination Effect of NKT-01 with Other Antitumor Agents The mechanismsof action of NKT-01were thought to be different from other antitumor agents such PE; plating efficiency =(number of colonies formed in soft agar)/(plated cell number) x 100. SF; surviving fraction = (PE of drug treatment)/(PE of control) x 100. daunorubicin) were larger compared with cell cycle specific agents such as antimetabolites (5-FU, Ara-C and methotrexate), an inhibitor of topoisomerase II (etoposide) and a mitotic inhibitor (vincristine). From these results, it could be postulated that the cytostatic effect of NKT-01limits the cell cycle progression of the tumor cells and decreased sensitive cell population to other agents passing through S phase to M phase, and then the cell cycle dependent effects of other agents were limited. Next, from the above viewpoints, we examined sequential combination of NKT-01in P388 leukemia. The results of the combinations of NKT-01with cyclophosphamide (CYC), CDDPand Ara-C in various sequences were shown in Tables 3, 4 and 5, respectively. According to the treatment schedule dependency of each drug, single administration schedule was employed for CYCand CDDP, and 5 daily schedule was used for Ara-C and NKT-01. The sequential combinations of NKT-01followed by these agents were also antagonistic in terms of combination index being less than 1.0, as well as the simultaneous combinations. In contrast, combinations in the reverse sequence, where the treatment with NKT-01followed the other agents, produced synergistic effects.
To further examine the differential effect of the sequence of the combination, we used a solid tumor system. M5076fibrosarcoma was inoculated sc and treated with 3 sequences of combination of NKT-01 and Ara-C as shown in Fig. 2 . NKT-01 at 25mg/kg/day and Ara-C at 80mg/kg/day as a single treatment for 5 days produced almost the same activity on the tumor volume of M5076fibrosarcoma. Growth inhibitory effect of the combination was superior to those of each single agent treatment in all sequences. CYCwas injected once on the indicated day at the dose of 80mg/kg. NKT-01 was injected daily for 5 days starting day 1 (day 1~5) at the dose of 25mg/kg/day, and CYCwas injected once as shownin the first column. NKT-01 was injected on day 5-9 and combined with CYC. a NKT-01 (25mg/kg/day) was injected daily for 5 days as shown by five arrows. b CDDP(2mg/kg) was injected once on the indicated day as shown by closed arrows. As is the same in the combination of NKT-01followed by Ara-C (CI=0.79), while the combination of Ara-C followed by NKT-01 inhibited the tumor growth synergistically over the sum of TGDof 2 single treatments (CI = 1.04). These sequence-dependent results obtained with M5076fibrosarcoma were consistent with those obtained in the combination experiments using P388 leukemia. These results in the sequential combination experiments support the assumption described above that tumor cells pretreated or simultaneously treated with NKT-01 were limited in ability to proceed through the cell cycle and showed decreased sensitivity to drugs following NKT-01.
Effect of NKT-01 on Cell Cycle Traverse In order to examine the effect of NKT-01on cell cycle traverse, DNAhistograms of P388 cells treated with NKT-01in vivo were measured with by flow cytometry after propidium iodide staining. As shown in Fig. 3 , NKT-01 decreased the cycling population in S and G2-Mphases and arrested the cells in G0/Gi phase (2c). Distribution of cell size was also shifted to smaller size than control cells. Noobvious difference was observed between the histograms obtained after 3 injections of NKT-01and 5 injections. These histograms of DNAcontent and cell size obtained after treatment with NKT-01were similar to those of late stage of control (day 8), of which a large population seems not to proliferate any more.
Analysis of Cell Cycle Perturbation in Sequential Combinations of NKT-01 and CDDP
To confirm the implication of the effect ofNKT-01on cell cycle traverse in combination chemotherapy, wefurther examine the DNAdistribution of P388 leukemia cells from the mice treated with NKT-01 combined with CDDP.The change of DNAhistograms by 3 sequential combinations as well as by single treatment were examined daily (Fig. 4 A to W) . The CDDP-caused synchronization of tumor cells in G2/Mphase was observed from the day after the injection. The arrest was maintained for about 4 days and recovered gradually (Fig. 4 C to E, and L to Q). The G2 blocking effect of CDDPinjected after or in the middle of 5 daily treatment of NKT-01was not remarkable until 3 days after the injection (Fig. 4 F to K) as compared with that by CDDPinjected alone. In contrast, in the case of combination of CDDP followed by NKT-01, G2 arrest caused by CDDPwas observed the day after the administration as seen in single injection. And the effect was prolonged until day 6, whereas cells treated with CDDPalone began to recover from day 4 and showed an almost normal pattern on day 6 as seen in control. Moreover, the effect of CDDPin this sequential combination was so intensified that cell population in Gx and S phases almost disappeared and that cells containing tetraploid DNAarose which were not obviously seen in the single treatment with CDDP (Fig. 4 R to W) . These results of cell cycle perturbation obtained in each sequential combination were consistent with the therapeutic combination effects in the corresponding sequences. In order to examine the nature of cell-killing of NKT-01in vivo, we estimated direct cell death by means of 125IUdR release and colony formation in soft agar. Apparent cell-killing was not observed in the early phase of NKT-01 treatment, and gradual cell death was detected after a few days. The strong effect of NKT-01to prolong survival time of tumor-bearing mice could not be explained by this weak cell-killing activity. Since the life prolonging activity is thought to be outcome from both the cytostatic effect and subsequent cell-kill action, the long lasting cytostatic activity in the early period contributes to the exhibition of antitumor efficacy. In the case of CDDP,which cross-links DNAstrands and directly kills tumor cells in a cell cycle non-specific manner, rapid excretion of 125I from mice was observed after the injection. The excretion of 125IUdR by 5-FU was delayed due to its cell cycle dependent antimetabolic effect, which mainly inhibits thymidylate synthetase. From this comparative experiment with CDDPand 5-FU, the effect ofNKT-01 seems to be cell cycle dependent and to require a long time to cause cell death. This nature of cell-killing of NKT-01could account for the strong dependency on exposure time in its exhibition of antitumor activity observed both in vitro and in vivo.5A0)
NKT-01 arrested the cells in G0IG1 phase and reduced the cycling cell population (Fig. 3) . Hiratsuka et al. also examined the effect of NKT-01on cell cycle progression of cultured L1210 leukemia cells.14) They clearly demonstrated the delay of cell cycle traverse using 5-bromo-2'-deoxyuridine and its fluorescent-labeled antibody with flow cytometry. Usual antitumor agents cause G2phase arrest with exceptions of mitotic inhibitors, which arrest cells in Mphase. Similar pattern of G0/Gi arrest was only clearly reported with tamoxifen, an effective antiestrogen,1 5) and difluoromethylornithine, an inhibitor of polyamine biosynthesis.16) Recent studies on regulation of cell cycling revealed that the conversion of Go cells to Gx phase and progression to S phase are two critical steps for cell proliferation,, and that many factors (for example, estrongen for mammarycells) and their signal transduction steps are involved in these steps of cell cycle.17'18) Therefore, it is possible to postulate that NKT-01may disturb the effect of such factors including oncogene/tumor suppressor gene products, and/or inhibit their signal transduction pathways.
In addition to antitumor effect, which was focused in the present studies, NKT-01has been shown to have potent immunosuppressive activities.7 '8) The cytostatic effect and Go/G1 blocking activity observed to tumor cells might be involved in the inhibition of immunological response and growth of immune cells aswell.
Since cycling cells have generally higher sensitivity than resting cells to usual antitumor agents, especially to cell cycle phase specific agents, the Go/G! arrest and delay of cell cycle traverse caused by NKT-01 decreased the efficacy of subsequent antitumor agents. This was also confirmed by the facts observed in the flow cytometry experiments; occurrence of G2 blockage by CDDPwas delayed by the pretreatment or simultaneous treatment with NKT-01.On the contrary, the combination effect was synergistic in the case that NKT-01was administered after the injection of other agents. This finding is consistent with the fact that the G2 arresting effect of CDDPwas intensified and lasted for longer period when it was followed by NKT-01. These results also indicate that NKT-01 not only arrests the cells in Go/G1 phase but also prolongs cycling time of cells passing through other phases. Combination effect was thought to be influenced by several factors such as combination sequence, drug dose ratio, treatment schedule of each drug and so on. In this study we showed the critical role of administration sequence in the combination of NKT-01.Other factors were not examined intensively in this study. Weused relatively low dose, which was expected to produce about 50%of ILS, rather than the optimal dose, to estimate the combination effect quantitatively, since combination of the optimal doses of two drugs might cure tumor-bearing mice and CI could not be calculated precisely. Also only single administration or 5-day daily treatment was selected for drug administration schedule due to similar practical reason. However, by changing the drug ratio, or schedule of each drug administration, more effective combination effect might be obtained. Although the details of mechanisms of action of NKT-01 remain to be solved, its effect on cell cycle traverse plays an important role not only in the exhibition of antitumor activity but also in the outcome of the therapeutic effect of the combination. Synergistic combination effects of NKT-01could be expected when it is administered after treatment with other antitumor drugs. This maybe supported by the facts NOV. 1991 that NKT-01has no cross-resistance to other antitumor agents and that NKT-01-resistant tumor cells shows collateral sensitivity especially to cell cycle non-specific antitumor agents.5)
